View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, Nov. 17 (HealthDay News) -- Use of over-the-counter pain medication during pregnancy -- particularly in the second trimester -- may increase the risk of congenital cryptorchidism, a finding which may explain recent marked increases in the incidence of this condition, according to research published online Nov. 8 in Human Reproduction.
David Møbjerg Kristensen, of the University of Copenhagen in Denmark, and colleagues conducted a prospective birth cohort study of 2,297 Danish and Finnish pregnant women to investigate the potential endocrine-disrupting properties of mild analgesics ingested during pregnancy, using congenital cryptorchidism in their male offspring as a measured outcome. The researchers also undertook a rat study of the effect of mild analgesics on anogenital distance (AGD) after intrauterine exposure.
The researchers found no significant association in the Finnish cohort (studied by questionnaire only), postulated to be because many women did not consider these analgesics to be "medications." In the Danish cohort (all completed a questionnaire and some a follow-up telephone interview), there was a dose-dependent association of mild analgesic intake with congenital cryptorchidism, especially in the second trimester; ibuprofen and aspirin approximately quadrupled the risk of cryptorchidism. Simultaneous use of more than one painkiller during the second trimester increased the risk 16-fold. In the rats, intrauterine exposure to mild analgesics was associated with a decrease in AGD.
"Collectively, the results [point] to a scenario where the use of mild analgesic medicine has a possible effect on fetal development with implications for later reproductive health," the authors write. "Therefore, more investigations are urgently needed and we will for our part continue to follow the boys in our cohorts, who currently are entering puberty."
The Novo Nordisk Foundation provided some funding for the study.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top